Gut safety of semaglutide and tirzepatide compared to placebo in obese people without diabetes

Overall GI adverse events were 1.86 times higher with both semaglutide and tirzepatide compared to placebo.

• Tirzepatide is associated with a greater risk of gastrointestinal adverse events than semaglutide, with a risk ratio of 2.94.
• Semaglutide increases the risk of gallbladder-related disorders, particularly cholelithiasis, by over 2.6 times.
• Tirzepatide does not show a significant biliary risk.
• Neither semaglutide nor tirzepatide significantly increases the risk of hepatic or pancreatic adverse events.
• Most gastrointestinal adverse events reported are mild.

Simplified